STRATIGOS, A.; SEKULIC, A.; PERIS, K.; BECHTER, O.; KAATZ, M.; LEWIS, K.; BASSET-SEGIUN, N.; CHANG, A. L.; DALLE, S.; ORLAND, A. F.; LICITRA, L.; ROBERT, C.; ULRICH, C.; HAUSCHILD, A.; MIGDEN, M.; DUMMER, R.; LI, S.; MOHAN, K.; COATES, E.; JANKOVIC, V.; FLASCHI, N.; OKOYE, E.; BASSUKAS, I.; LOQUAI, C.; DE GIORGI, V.; EROGLU, Z.; GUTZMER, R.; ULRICH, J.; PUIG, S.; SEEBACH, F.; THURSTON, G.; LOWY, I.; BOWLER, T.; FURY, M. Primary Analysis of Phase 2 Results for Cemiplimab in Patients (pts) with Locally Advanced Basal Cell Carcinoma (laBCC) who Progress on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s4, 2021. DOI: 10.25251/skin.5.supp.4. Disponível em: https://jofskin.org/index.php/skin/article/view/1156. Acesso em: 29 mar. 2024.